A detailed history of Cormorant Asset Management, LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,550,000 shares of URGN stock, worth $17.3 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares
1,550,000
Previous 1,650,000 6.06%
Holding current value
$17.3 Million
Previous $27.7 Million 28.9%
% of portfolio
1.38%
Previous 2.13%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.7 - $17.92 $1.27 Million - $1.79 Million
-100,000 Reduced 6.06%
1,550,000 $19.7 Million
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $21 Million - $31.7 Million
1,650,000 New
1,650,000 $27.7 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $254M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.